Loading...
More than 1.5 million people each year suffer a traumatic brain injury (TBI), and many have complications such as persistent cognitive dysfunction, post-concussive syndrome, mood disorders, and post-traumatic stress disorder. Cholinergic deficits are thought to play a role in post-TBI cognitive dysfunction.
In a 12-week, multicenter, industry-sponsored, randomized, double-blind study, researchers compared placebo and rivastigmine (mean dosage, 5.4 mg/day), which inhibits acetylcholinesterase and butyrylcholinesterase. The 157 participants had experienced closed-head injuries, often with unconsciousness, an average of 6 years previously and had a variety of residual psychiatric and neurological symptoms; 85% completed the trial.
The rivastigmi…